Hogan Lovells advises Villaris Therapeutics in US$70 million acquisition for vitiligo antibody
Press releases
| 05
October
2022
Washington, D.C., 5 October 2022 – Global law firm Hogan Lovells advised Villaris Therapeutics, a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo, in a sale to global pharmaceutical company Incyte. Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize Villaris’ lead asset, monoclonal antibody auremolimab, for all uses, including for vitiligo and other autoimmune and inflammatory diseases. Further details can be found here.
Villaris’ shareholders will receive US$70 million in upfront payments and be eligible for up to US$310 million upon achievement of certain development and regulatory milestones, as well as up to an additional US$1.05 billion in commercial milestones on net sales of the product.
Hogan Lovells’ cross-office, cross-practice legal team was led by Washington, D.C.-based partner Meg McIntyre and Philadelphia-based partner Denis Segota, with support from the following:
Hogan Lovells’ cross-office, cross-practice legal team was led by Washington, D.C.-based partner Meg McIntyre and Philadelphia-based partner Denis Segota, with support from the following:
- New York Office Managing Partner Michael DeLarco
- Partner Matt Eisler, Denver
- Partner Ajay Kuntamukkala, Washington, D.C.
- Counsel Robert Baldwin, New York
- Senior Associate Caitlin R. Piper, Washington, D.C.
- Senior Associate Sarah Thompson Schick, Houston
- Senior Associate Kareem Ratani, Denver
- Associate Maria Benvenuto, New York
- Associate Jason Lee, New York
- Associate Dan Ongaro, Minneapolis
- Associate Shirley Ureña, New York
- Law Clerk Elizabeth F. Adams, Washington, D.C.
Press contacts
Press contacts